Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation.
Dendritic cells (DCs) are fundamental for immunity. We investigated reconstitution of plasmacytoid DC (PDC) and myeloid DC (My-DC) precursors in the first 2 months after allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Circulating DCs were monitored from the earliest phase of hematopoietic reconstitution in 43 children given standard therapy to prevent graft-versus-host disease (GVHD) and either treated or untreated with granulocyte colony-stimulating factor (G-CSF) after HSCT. In patients without GVHD, both My-DCs and PDCs reached consistently high absolute values during the initial phase. Time of engraftment did not differ between My-DCs and PDCs, regardless of administration of G-CSF. Treatment with G-CSF (1) accelerated early recovery of My-DC absolute numbers; (2) was associated with lower numbers of both My-DCs and PDCs in the later phase; and (3) significantly reduced the proportion of interleukin-12 (IL-12)-secreting cells. In some patients who developed acute GVHD, we found high numbers of circulating DC precursors during the early phase of this complication. However, treatment with steroids invariably induced rapid decrease of PDCs. Altogether, these data provide an evaluation of DC release after Allo-HSCT, indicate that postgrafting administration of G-CSF impairs the appearance of IL-12-producing DCs, and suggest that DC homeostasis may be disrupted at onset of GVHD.
Fagnoni
Francesco F
FF
Dipartimento di Oncologia, Fondazione S. Maugeri, Istituto di Ricovero e Cura a Carattere Scientifico Clinica del Lavoro e della Riabilitazione, Istituto Scientifico di Pavia, Italy. ffagnoni@fsm.it
Oliviero
Barbara
B
Giorgiani
Giovanna
G
De Stefano
Piero
P
Dehò
Anna
A
Zibera
Carlo
C
Gibelli
Nadia
N
Maccario
Rita
R
Da Prada
GianAntonio
G
Zecca
Marco
M
Locatelli
Franco
F
D000293:Adolescent; D015703:Antigens, CD / Q000276:immunology; D016022:Case-Control Studies; D002454:Cell Differentiation; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology / Q000648:ultrastructure; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000276:immunology / Q000494:pharmacology; D008297:Male; D022423:Myeloid Cells / Q000166:cytology* / Q000276:immunology / Q000648:ultrastructure; D010950:Plasma Cells / Q000166:cytology* / Q000276:immunology / Q000648:ultrastructure; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D011446:Prospective Studies; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects* / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D015703:Antigens, CD; D016207:Cytokines; D008070:Lipopolysaccharides; D013256:Steroids; D016179:Granulocyte Colony-Stimulating Factor